GlassScriptPhysician profile
Nancy A Huff
NPI 1912981648
$16,308.69
in general payments reported to CMS, 2019-2025
50 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,929 · 2020: $397 · 2021: $2,757 · 2022: $937 · 2023: $3,984 · 2024: $2,205 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,493 · Travel and Lodging: $1,726 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,493.46 |
| Travel and Lodging | $1,726.31 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $5,129.35 | 2021-2024 | Bulkamid, Axonics |
| Coloplast Corp | $4,999.71 | 2019-2024 | Altis, Speedicath, Saffron |
| Medtronic USA, INC. | $1,647.76 | 2019 | |
| Boston Scientific Corporation | $560.91 | 2019-2025 | Axonics, Spaceoar Vue System - 10ml |
| Astellas Pharma US INC | $532.32 | 2019-2025 | Xtandi |
| Teleflex LLC | $401.68 | 2024-2025 | Barrigel, Urolift |
| Abbvie INC. | $319.28 | 2019-2025 | |
| Medtronic, INC. | $293.12 | 2021-2023 | Interstim |
| Biotissue Holdings INC. | $251.95 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $182.66 | 2023-2025 | Orgovyx, Gemtesa |
| Myovant Sciences INC. | $173.48 | 2021 | |
| Ferring Pharmaceuticals INC. | $157.95 | 2019-2024 | Adstiladrin |
| Janssen Biotech, INC. | $137.08 | 2019-2025 | Erleada |
| Eisai INC. | $125.00 | 2023 | |
| Pfizer INC. | $116.99 | 2019-2024 |
Show all 49 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$100,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Huff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.